{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:48:20Z","timestamp":1778881700936,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1053\/j.seminoncol.2016.11.003","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T08:47:46Z","timestamp":1478335666000},"page":"700-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of newly diagnosed myeloma: Bortezomib-based triplet"],"prefix":"10.1053","volume":"43","author":[{"given":"Archana M.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.11.003_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib2","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib3","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib4","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib6","unstructured":"Durie BGM, Hoering A, Abidi MH, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone induction followed by lenalidomide and dexamethasone maintenance in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant: results of the randomised phase III SWOG trial S0777. Lancet [In press]."},{"key":"10.1053\/j.seminoncol.2016.11.003_bib7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib8","first-page":"A391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial)","volume":"126","author":"Attal","year":"2015","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib10","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib11","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib13","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib15","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.mayocp.2013.05.012","article-title":"A decade of reversal: an analysis of 146 contradicted medical practices","volume":"88","author":"Prasad","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2016.11.003_bib18","unstructured":"The ENDEAVOR trial: a case study in the interpretation of modern cancer trials. ASCO, 2016. Accessed September 9, 2016, at http:\/\/www.ascopost.com\/issues\/june-10-2016\/the-endeavor-trial-a-case-study-in-the-interpretation-of-modern-cancer-trials\/."},{"key":"10.1053\/j.seminoncol.2016.11.003_bib19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood-2015-07-657478","article-title":"How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses","volume":"126","author":"Prasad","year":"2015","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416301130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416301130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T23:50:24Z","timestamp":1536277824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416301130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0093775416301130"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.003","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of newly diagnosed myeloma: Bortezomib-based triplet","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}